Clearstead Advisors’s Viridian Therapeutics VRDN Stock Holding History

Clearstead Advisors’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92.4K	Sell	5,029 -4,971	-50%	-$80.1K	﹤0.01%	1318
2026 Q1	$196K	Buy	10,000 +5,000	+100%	+$148K	﹤0.01%	999
2025 Q4	$156K	Hold	5,000	–	–	﹤0.01%	984
2025 Q3	$108K	Buy	5,000 +4,874	+3,868%	+$87.9K	﹤0.01%	1029
2025 Q2	$1.76K	Hold	126	–	–	﹤0.01%	2351
2025 Q1	$1.7K	Hold	126	–	–	﹤0.01%	1925
2024 Q4	$2.42K	Hold	126	–	–	﹤0.01%	1822
2024 Q3	$2.87K	Hold	126	–	–	﹤0.01%	1795
2024 Q2	$1.64K	Buy	+126	New	+$1.74K	﹤0.01%	1837

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Clearstead Advisors's VRDN Position: Q2 2026 in Review

Clearstead Advisors reduced its Viridian Therapeutics (VRDN) stake by 50% in Q2 2026, selling an estimated $80.1K and leaving 5,029 shares worth $92.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1318.

Clearstead Advisors first reported a position in VRDN in Q2 2024 and has held it in 9 quarters since. The position peaked at $196K in Q1 2026. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Clearstead Advisors held 5,029 shares of Viridian Therapeutics worth $92.4K as of Q2 2026.
Clearstead Advisors sold 4,971 Viridian Therapeutics shares in Q2 2026, an estimated $80.1K.
Viridian Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1318 holding.
Clearstead Advisors first reported a position in Viridian Therapeutics in Q2 2024 and has held it in 9 quarters since.
Clearstead Advisors's Viridian Therapeutics position peaked at $196K in Q1 2026.
215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.